Final - February 22, 2021

PRESIDER/PRESENTER(s)

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

10:00 Rabies Vaccines

Introduction

Rabies pre-exposure prophylaxis: summary of background information 

Rabies pre-exposure prophylaxis: summary of Evidence to Recommendations 

Approach to rabies post-exposure prophylaxis 

Work group interpretations of data about rabies immune globulin and next 

steps for the WG 

Dr. Sharon Frey (ACIP, WG Chair)

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

12:00

12:30

1:00 Votes

Dr. Agam Rao (CDC/NCEZID)

1:20 Dengue Vaccine

Introduction

Results of dengue test independent evaluation

Workgroup interpretation

Dr. Kathy Poehling (ACIP, WG Chair)

Dr. Freddy Medina (CDC/NCEZID)

Dr. Gabriela Paz-Bailey (CDC/NCEZID)

2:20 Tick-borne Encephalitis (TBE) Vaccine

Introduction

TBE epidemiology in TBE endemic areas

TBE among US civilian travelers and laboratory workers

TBE among military personnel and dependents

Summary of risks of TBE for U.S. travelers and laboratory workers and next 

steps

Dr. Kathy Poehling (ACIP, WG Chair)

Dr. Susan Hills (CDC/NCEZID)

Dr. Erin Staples (CDC/NCEZID)

Dr. Bruce McClenathan (DOD)

Dr. Susan Hills (CDC/NCEZID)

3:30

3:40 Ebola Vaccine

Introduction

Background on state designated Ebola Treatment Centers (ETC) and Laboratory 

Response Network (LRN) facilities and survey results

Review of preliminary workgroup discussions

Dr. Sharon Frey (ACIP, WG Chair)

Ms. Allison Joyce (CDC/NCEZID)

Dr. Caitlin Cossaboom (CDC/NCEZID)

4:45 Hepatitis Vaccine

Introduction

Background 

Economic analysis

Dr. Sharon Frey (ACIP, WG Chair)

Dr. Mark Weng (CDC/NCHHSTP)

Dr. Eric Hall (Emory University)

5:30

Dr. José Romero (ACIP Chair)

Dr. Amanda Cohn (ACIP Executive Secretary, CDC)

9:40

10:00 Pneumococcal Vaccines

Introduction

Current epidemiology of pneumoccocal disease and pneumococcal vaccine 

coverage in US adults

PCV20 Phase 2/3 study results in adults

PCV15 Phase 2/3 study results in adults, including adults with underlying 

conditions

Considerations for PCV15 and PCV 20 use in adults

Dr. Kathy Poehling (ACIP, WG Chair)

Mr. Ryan Gierke (CDC/NCIRD)

Dr. Wendy Watson (Pfizer)

Dr. Ulrike Buchwald (Merck)

Dr. Miwako Kobayashi (CDC/NCIRD)

12:00

12:20 Zoster Vaccines

Introduction

Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine 

(RZV)

RZV risk-benefit analysis

Work group interpretation

Introduction of the Evidence to Recommendations Framework for use of RZV in 

immunocompromised adults

Dr. Grace Lee (ACIP, WG Chair)

Dr. Richard Forshee (FDA/CBER)

Dr. Lisa Prosser (University of Michigan)

Dr. Tara Anderson (CDC/NCIRD)

Dr. Tara Anderson (CDC/NCIRD)

Break

Adjourn

Thursday, February 25, 2021

9:30 Welcome & Introductions

Wednesday, February 24, 2021

9:30 Welcome & Introductions

Break

Rabies Vaccines

Public Comment

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329 

February 24-25, 2021

AGENDA ITEM

Break

Agency Updates

page 1 of 2
Final - February 22, 2021

1:30 Influenza Vaccines

Introduction

Influenza surveillance update

Work group considerations

Dr. Keipp Talbot (ACIP, WG Chair)

Dr. Lisa Grohskopf (CDC/NCIRD)

Dr. Lisa Grohskopf (CDC/NCIRD)

2:15

2:25 Cholera Vaccine

Introduction

Introduction to cholera and cholera vaccines

Vaxchora safety and immunogenicity data

Work group plans

Dr. Pablo Sanchez (ACIP, WG Chair)

Dr. Jennifer Collins (CDC/NCEZID)

Dr. James McCarty (Emergent BioSolutions)

Dr. Jennifer Collins (CDC/NCEZID)

3:25 Orthopoxviruses Vaccines

Introduction and use of Vaccinia virus vaccine in persons at risk for occupational 

exposure to orthopoxviruses: WG update 

Workgroup considerations 

Updated policy questions for EtR Framework and plan for next steps 

Dr. Beth Bell (ACIP, WG Chair)

Dr. Brett Petersen (CDC/NCEZID)

Dr. Agam Rao (CDC/NCEZID)

5:00

Acronyms

CDC

CMS

COVID-19

EtR

FDA

GRADE

HRSA

IHS

NCHHSTP

NCIRD

NCEZID

NIAID

OIDP

PCV15 

PCV20 

PEP

PrEP

RZV

SARS-CoV-2

WG

WHO

VE

Evidence to Recommendations Framework

Food and Drug Administration

Break

Adjourn

Coronavirus disease 2019

Centers for Disease Control and Prevention

Health Resources and Services Administration

Indian Health Service

Grading of Recommendations Assessment, Development and Evaluation

Centers for Medicare and Medicaid Services

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

World Health Organization

Vaccine Effectiveness

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

National Institute of Allergy and Infectious Diseases

Office of Infectious Disease and HIV/AIDS Policy

Severe acute respiratory syndrome coronavirus 2

Work Group

Post-exposure prophylaxis

Pre-exposure prophylaxis

15-valent pneumococcal conjugate vaccine 

20-valent pneumococcal conjugate vaccine 

Recombinant zoster vaccine

page 2 of 2